Core C: Viral Evolution

  • Funded by National Institutes of Health (NIH)
  • Total publications:0 publications

Grant number: 1P01AI167966-01

Grant search

Key facts

  • Disease

    COVID-19, Severe Acute Respiratory Syndrome (SARS)
  • Start & end year

    2022
    2025
  • Known Financial Commitments (USD)

    $1,225,278
  • Funder

    National Institutes of Health (NIH)
  • Principal Investigator

    Jesse Bloom
  • Research Location

    United States of America
  • Lead Research Institution

    UNIVERSITY OF WASHINGTON
  • Research Priority Alignment

    N/A
  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Pathogen genomics, mutations and adaptations

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

PROJECT SUMMARY - CORE C: VIRAL EVOLUTION The Viral Evolution Core will develop tools to inform the engineering of vaccines that broadly target coronaviruses that pose a pandemic risk. To do this, the core will use deep mutational scanning to define the biochemical and functional properties of RBDs and spikes across the full evolutionary span of sarbecoviruses and merbecoviruses, and systematically map how these proteins are targeted by vaccine-elicited antibody immunity. In the first aim, we will measure the receptor-binding properties of all known sarbecovirus and merbecovirus RBDs to identify key strains of interest and inform the development of animal models (Core B: Virology, Baric). In the second aim, we will develop a system to measure how all mutations to the spikes from key strains affect cell entry, thereby identifying functionally constrained epitopes to target with vaccines. In the third aim, we will use the RBD and spike libraries to quantify the binding breadth and robustness to mutations of vaccine elicited monoclonal and polyclonal antibodies, thereby providing direct functional readouts to rapidly assess candidate vaccines and inform their further engineering.